Table 2.
Odds ratios (ORs) and 95% confidential intervals (CIs) for pCR in all patients.
| Univariate | Multivariate | |||
|---|---|---|---|---|
| OR (95% CIs) | P-value | OR (95% CIs) | P-value | |
| Age | 0.996 (0.982–1.011) | 0.62 | 0.992 (0.977–1.008) | 0.336 |
| NLR | ||||
| < 2.74 | Ref | Ref | ||
| ≥ 2.74 | 0.680 (0.476–0.971) | 0.034 | 0.595 (0.398–0.890) | 0.011 |
| cT stage | 0.002 | < 0.001 | ||
| 1 | Ref | Ref | ||
| 2 | 1.320 (0.856–2.036) | 0.209 | 0.804 (0.489–1.324) | 0.392 |
| 3 | 0.596 (0.336–1.056) | 0.076 | 0.327 (0.172–0.621) | 0.001 |
| cN stage | ||||
| Negative | Ref | Ref | ||
| Positive | 0.407 (0.285–0.582) | < 0.001 | 0.583 (0.385–0.883) | 0.011 |
| ER | ||||
| Positive | Ref | Ref | ||
| Negative | 7.713 (5.462–10.892) | < 0.001 | 5.017 (3.033–8.299) | < 0.001 |
| PR | ||||
| Positive | Ref | Ref | ||
| Negative | 7.515 (5.034–11.220) | < 0.001 | 2.283 (1.289–4.044) | 0.005 |
| Regimen | 0.002 | < 0.001 | ||
| AC-T | Ref | Ref | ||
| AC | 0.516 (0.198–1.345) | 0.176 | 0.407 (0.142–1.168) | 0.095 |
| AT | 0.381 (0.225–0.644) | < 0.001 | 0.308 (0.174–0.544) | < 0.001 |
| Others* | 0.941 (0.457–1.939) | 0.870 | 0.741 (0.333–1.651) | 0.463 |
pCR pathologic complete response, NLR neutrophil to lymphocyte ratio, cT clinical T stage, cN clinical N stage, ER estrogen receptor, PR progesterone receptor, AC-T doxorubicin and cyclophosphamide followed by taxane, AC doxorubicin and cyclophosphamide, AT doxorubicin and taxane.
*Others: cyclophosphamide, doxorubicin, 5-fluorouracil (CAF); cyclophosphamide, methotrexate, 5-fluorouracil (CMF); taxane; taxane plus carboplatin.